This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aldridge, K. E.
Right arrow Articles by Sanders, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aldridge, K. E.
Right arrow Articles by Sanders, C. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 148-153, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.148-153.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Bacteremia Due to Bacteroides fragilis Group: Distribution of Species, ß-Lactamase Production, and Antimicrobial Susceptibility Patterns

Kenneth E. Aldridge,* Deborah Ashcraft, Megan O'Brien, and Charles V. Sanders

Department of Medicine (Infectious Diseases), Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112

Received 22 April 2002/ Returned for modification 14 June 2002/ Accepted 24 September 2002

A retrospective analysis of susceptibility data on 542 blood isolates of the Bacteroides fragilis group tested from 1987 to 1999 by the same NCCLS-recommended broth microdilution method throughout is presented. Metronidazole, ß-lactam-ß-lactamase inhibitor combinations, carbapenems, and trovafloxacin were the most active agents (susceptibility of >=93%). Among the cephalosporin-cephamycins, the order of activity was cefoxitin > ceftizoxime > cefotetan = cefotaxime = cefmetazole > ceftriaxone. All isolates were resistant to penicillin G, and 22% were resistant to clindamycin. The susceptibility rates to piperacillin-tazobactam, imipenem, and meropenem were affected least among isolates resistant to cefoxitin or clindamycin. Except for piperacillin-tazobactam, imipenem, and meropenem, the B. fragilis species was more susceptible than were the non-B. fragilis species. These data underscore the importance of susceptibility testing of the B. fragilis group and can serve as a guide in the choice of empirical antimicrobial therapy.

* Corresponding author. Mailing address: Department of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Ave., New Orleans, LA 70112. Phone: (504) 568-5031. Fax: (504) 568-2127. E-mail: kaldri{at}lsuhsc.edu.

Antimicrobial Agents and Chemotherapy, January 2003, p. 148-153, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.148-153.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Goldstein, E. J. C., Citron, D. M., Warren, Y. A., Tyrrell, K. L., Merriam, C. V., Fernandez, H. (2006). In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections. Antimicrob. Agents Chemother. 50: 148-155 [Abstract] [Full Text]  
  • Ueda, O., Wexler, H. M., Hirai, K., Shibata, Y., Yoshimura, F., Fujimura, S. (2005). Sixteen Homologs of the Mex-Type Multidrug Resistance Efflux Pump in Bacteroides fragilis. Antimicrob. Agents Chemother. 49: 2807-2815 [Abstract] [Full Text]  
  • Edmiston, C. E., Krepel, C. J., Seabrook, G. R., Somberg, L. R., Nakeeb, A., Cambria, R. A., Towne, J. B. (2004). In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot Infections. Antimicrob. Agents Chemother. 48: 1012-1016 [Abstract] [Full Text]  
  • Elsaghier, A. A. F., Brazier, J. S., James, E. A. (2003). Bacteraemia due to Bacteroides fragilis with reduced susceptibility to metronidazole. J Antimicrob Chemother 51: 1436-1437 [Full Text]  
  • (2003). B. fragilis Group Bacteremia -- What's the Optimal Antibiotic?. JWatch Infect. Diseases 2003: 5-5 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»